

Supplement

Nguyen, S., Nguyen, D., Dang, V., Doan, B., Dinh, B., Nguyen, T., Nguyen, C., & Pham, D. (2024). Assessing LDL Cholesterol Management and Statin Use in Diabetic Patients: Disparities and Outcomes in a Vietnamese Tertiary Hospital Setting. *Biomedical Research and Therapy*, 11(4), 6297-6304. <https://doi.org/10.15419/bmrat.v11i4.876>

Table S1. Baseline characteristics of the participants (target vs. not-at-target groups)				
	Total (N = 515)	Target (N = 79)	Not-at-target (N = 436)	P-value
Demographic features				
Female	290 (56.3)	37 (46.8)	253 (58.0)	0.065
Age	66 (66-72)	66 (59-72)	66 (60-72)	0.273
Comorbidities				
Hypertension	500 (97.1)	78 (98.7)	422 (96.8)	0.344
CCS	246 (47.8)	25 (31.7)	221 (50.7)	< 0.05
Heart failure	25 (4.9)	4 (5.1)	21 (4.8)	0.925
Atrial fibrillation	30 (5.8)	8 (10.1)	22 (5.1)	0.076
Stroke	13 (2.5)	0 (0)	13 (3.0)	0.120
PAD	3 (0.6)	0 (0)	3 (0.7)	0.460
CKD	48 (9.3)	12 (15.2)	36 (8.3)	0.051
Thyroid disease	12 (2.4)	2 (2.6)	10 (2.3)	0.938
Lung disease	5 (1.0)	0 (0)	5 (1.1)	0.339
Joint disease	44 (8.5)	7 (8.9)	37 (8.5)	0.913
Laboratory results				
Hemoglobin (g/L)	135 (124-144)	137(125-144)	135(134-144)	0.609
HbA1C (%)	6.6 (6.0-7.6)	6.4 (5.8-7.6)	6.7(6.0-7.7)	0.182
Creatinine (umol/L)	88.5 (76-104.4)	89 (76.1-107.7)	88.4(76-104)	0.929
AST (IU/L)	26 (21.8-32)	26.7 (22.4-36.5)	26 (21.8-31.7)	0.112
ALT (IU/L)	25.6 (18.5-37.6)	28.3 (21-42)	25.1 (18-36)	0.085
Cholesterol (mmol/L)	4.0 (3.3-4.9)	3 (2.6-3.3)	4.2 (3.7-5.0)	< 0.05
Triglyceride (mmol/L)	1.8 (1.3-2.6)	1.6(1.1-2.4)	1.9 (1.3-2.6)	0.174
HDL cholesterol (mmol/L)	1.1 (1.0-1.3)	1.0 (0.9-1.2)	1.2 (1.0-1.3)	< 0.05
LDL cholesterol (mmol/L)	2.2 (1.9-3.0)	1.3 (1.1-1.5)	2.5 (2.0-3.1)	< 0.05
TG/HDL	1.7 (1.1-2.5)	1.7 (1.1-2.5)	1.7 (1.0-2.5)	0.358
TG/LDL	0.8 (0.6-1.1)	1.3 (0.8-2.0)	0.7 (0.5-1.0)	< 0.05
Cardiovascular risk				
High	249 (48.4)	54 (68.4)	195 (44.7)	< 0.05
Very high	266 (51.6)	25 (31.7)	241 (55.3)	
Medications				
ARNI	2 (0.4)	0	2 (0.5)	< 0.05

Supplement

Nguyen, S., Nguyen, D., Dang, V., Doan, B., Dinh, B., Nguyen, T., Nguyen, C., & Pham, D. (2024). Assessing LDL Cholesterol Management and Statin Use in Diabetic Patients: Disparities and Outcomes in a Vietnamese Tertiary Hospital Setting. *Biomedical Research and Therapy*, 11(4), 6297-6304. <https://doi.org/10.15419/bmrat.v11i4.876>

ACE inhibitors	98 (19.0)	16 (20.2)	82 (18.8)	0.763
ARBs	321 (62.3)	47 (59.5)	247 (62.8)	0.572
BBs	360 (69.9)	50 (63.3)	310 (71.1)	0.164
CCBs	264 (51.3)	37 (46.8)	227 (52.1)	0.392
Diuretics	122 (23.7)	26 (32.9)	96 (22.0)	< 0.05
MRAs	25 (4.9)	1 (1.3)	24 (5.5)	0.153
Aspirin	73 (14.2)	4 (5.1)	69 (15.8)	< 0.05
P2Y12 inhibitors	126 (24.5)	15 (19.0)	111 (25.5)	0.218
VKAs	10 (1.9)	3 (3.0)	7 (1.6)	0.194
DOACs	20 (3.9)	6 (7.6)	14 (3.2)	0.063
Insulin	70 (13.6)	17 (21.5)	53 (12.2)	< 0.05
Metformin	314 (61.0)	50 (63.3)	264 (60.1)	0.646
SGLT2 inhibitors	3 (0.6)	1 (1.3)	2 (0.5)	0.394
DPP4 inhibitors	3 (0.6)	1 (1.3)	2 (0.5)	0.394
Sulfonylureas	197 (38.3)	34 (43.0)	163 (37.4)	0.342
Acarbose	65 (12.6)	11 (13.9)	54 (12.4)	0.705
Lipid-lowering agents				
Statin				
Atorvastatin	345 (70.7)	44 (56.4)	301 (73.4)	< 0.05
Rosuvastatin	141 (28.9)	34 (43.6)	107 (26.1)	
Simvastatin	2 (0.4)	0	2 (0.5)	
Statin intensity				
High	34 (6.6)	8 (10.1)	26 (6.0)	0.170
Intermediate	454 (88.2)	70 (88.6)	384 (88.1)	0.892
Others				
Fibrates	30 (5.8)	1 (1.3)	29 (6.7)	0.060
Ezetimibe	6 (1.2)	1 (1.3)	5 (1.2)	1.000
ACE: angiotensin-converting enzyme, ALT: alanine transaminase, ARB: angiotensin receptor blocker, ARNI: sacubitril/valsartan, AST: aspartate transaminase, BB: beta blocker, CCB: calcium channel blocker, CCS: chronic coronary syndrome, CKD: chronic kidney disease, DOAC: direct oral anticoagulant, DPP4: dipeptidyl peptidase 4, HDL: high-density lipoprotein, LDL: low-density lipoprotein, MRA: mineralocorticoid receptor antagonist, PAD: peripheral arterial disease, SGLT2: sodium-glucose cotransporter 2, TG: triglyceride, VKA: vitamin K antagonists.				